Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Next Previous
Trial Profile

A Phase 1/2 Study of DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Tulmimetostat (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; B-cell lymphoma; Bladder cancer; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Diffuse large B cell lymphoma; Endometrial cancer; Gastric cancer; Leiomyosarcoma; Lymphoma; Malignant melanoma; Mesothelioma; Ovarian cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; T-cell lymphoma; Urogenital cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Constellation Pharmaceuticals

Most Recent Events

  • 15 May 2025 Planned number of patients changed from 210 to 275.
  • 15 May 2025 Planned End Date changed from 1 Mar 2026 to 27 Feb 2030.
  • 15 May 2025 Planned primary completion date changed from 31 Dec 2025 to 27 Feb 2030.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top